Glutathione S-transferase Mu 2 (GSTM2) has been identified in aggressive, high-grade breast tumors where promoter hypermethylation is associated with ER/PR-negative status among ductal carcinoma in situ (DCIS) and invasive tissue components [33]. Here, PGR is linked to ductal breast carcinoma in situ.